Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 25, 2025
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
GlobeNewswire
·
March 25, 2025
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger Waltzman, M.D., …
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
GlobeNewswire
·
March 25, 2025
RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and …
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
GlobeNewswire
·
March 25, 2025
ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), …
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025
GlobeNewswire
·
March 25, 2025
WILMINGTON, DE, March 25, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), a global medical technology innovator, will feature its expanding portfolio of foot and ankle solutions at this year’s American College of Foot …
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
GlobeNewswire
·
March 25, 2025
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep Global Phase III with efti will enrol approximately 756 patients at more than 150 clinical sites Trial results will inform potential …
Save the Date: Profound Medical to Host Investor Event at AUA 2025
GlobeNewswire
·
March 25, 2025
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased …
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
GlobeNewswire
·
March 25, 2025
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
MUHC Foundation Receives $2 million Donation to establish the MUHC’s Metabolic Centre of Excellence
GlobeNewswire
·
March 25, 2025
MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- The McGill University Health Centre (MUHC) Foundation is proud to announce a $2 million donation from Novo Nordisk Canada Inc. to support the establishment of the Metabolic Centre of Excellence at the MUHC. This …
La Fondation du CUSM reçoit un don de 2 millions de dollars pour établir le Centre d’excellence en métabolisme du CUSM
GlobeNewswire
·
March 25, 2025
MONTRÉAL, 25 mars 2025 (GLOBE NEWSWIRE) -- La Fondation du Centre universitaire de santé McGill (CUSM) est fière d’annoncer un don de 2 millions de dollars de Novo Nordisk Canada dédié à la création du Centre d’excellence en métabolisme du CUSM. Cette …
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
GlobeNewswire
·
March 25, 2025
HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed …
Prime Biome Reviews (Is It Legit And Safe Ingredients?) Can This Probiotic Really Transform Your Skin And Gut?
GlobeNewswire
·
March 25, 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- The Prime Biome probiotic supplement that has been garnering attention in the health supplement industry is a unique aid made with the intention of supporting the health of the skin and the gut naturally. Composed …
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 25, 2025
GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today …
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
GlobeNewswire
·
March 25, 2025
PURCHASE, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, will be presenting biomarker results from the …
Enable Injections Announces Regulatory CE Mark Approval in Europe for enFuse Technology
GlobeNewswire
·
March 25, 2025
CINCINNATI, March 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform, today announced it has received its European Union Medical Device …
CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 25, 2025
‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- …
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
GlobeNewswire
·
March 25, 2025
Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent Protection for QRX003 for Netherton …
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
GlobeNewswire
·
March 25, 2025
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62,000 newly diagnosed patients annually) …
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
GlobeNewswire
·
March 25, 2025
Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimen Preparations are underway for FDA interactions and initiation of …
Aurora Spine Announces FDA 510(k) Clearance for the AERO™ Facet Fusion System
GlobeNewswire
·
March 25, 2025
CARLSBAD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced that the U.S. Food and …
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
GlobeNewswire
·
March 25, 2025
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention of …